The  ||| S:0 E:4 ||| DT
science  ||| S:4 E:12 ||| NN
and  ||| S:12 E:16 ||| CC
manufacturing  ||| S:16 E:30 ||| NN
behind  ||| S:30 E:37 ||| IN
botulinum  ||| S:37 E:47 ||| JJ
neurotoxin  ||| S:47 E:58 ||| JJ
type  ||| S:58 E:63 ||| NN
A-ABO  ||| S:63 E:69 ||| NN
in  ||| S:69 E:72 ||| IN
clinical  ||| S:72 E:81 ||| JJ
use  ||| S:81 E:85 ||| NN
Since  ||| S:85 E:91 ||| IN
the  ||| S:91 E:95 ||| DT
first  ||| S:95 E:101 ||| JJ
comprehensive  ||| S:101 E:115 ||| JJ
description  ||| S:115 E:127 ||| NN
of  ||| S:127 E:130 ||| IN
the  ||| S:130 E:134 ||| DT
physiologic  ||| S:134 E:146 ||| JJ
effects  ||| S:146 E:154 ||| NNS
of  ||| S:154 E:157 ||| IN
botulism  ||| S:157 E:166 ||| JJ
toxicity  ||| S:166 E:175 ||| NN
in  ||| S:175 E:178 ||| IN
the  ||| S:178 E:182 ||| DT
1820s ||| S:182 E:187 ||| NNP
,  ||| S:187 E:189 ||| ,
specific  ||| S:189 E:198 ||| JJ
formulations  ||| S:198 E:211 ||| NNS
of  ||| S:211 E:214 ||| IN
botulinum  ||| S:214 E:224 ||| JJ
neurotoxin  ||| S:224 E:235 ||| JJ
type  ||| S:235 E:240 ||| NN
A  ||| S:240 E:242 ||| DT
( ||| S:242 E:243 ||| -LRB-
BoNT-A ||| S:243 E:249 ||| NNP
)  ||| S:249 E:251 ||| -RRB-
have  ||| S:251 E:256 ||| VBP
been  ||| S:256 E:261 ||| VBN
developed ||| S:261 E:270 ||| VBN
.  ||| S:270 E:272 ||| .
Now ||| S:272 E:275 ||| RB
,  ||| S:275 E:277 ||| ,
a  ||| S:277 E:279 ||| DT
new  ||| S:279 E:283 ||| JJ
botulinum  ||| S:283 E:293 ||| JJ
neurotoxin  ||| S:293 E:304 ||| JJ
type  ||| S:304 E:309 ||| NN
A  ||| S:309 E:311 ||| DT
formulation  ||| S:311 E:323 ||| NN
( ||| S:323 E:324 ||| -LRB-
BoNTA-ABO ||| S:324 E:333 ||| NNP
;  ||| S:333 E:335 ||| :
Dysport  ||| S:335 E:343 ||| NNP
[ ||| S:343 E:344 ||| -LRB-
abobotulinumtoxinA ||| S:344 E:362 ||| NNP
] ||| S:362 E:363 ||| -RRB-
;  ||| S:363 E:365 ||| :
Medicis  ||| S:365 E:373 ||| NNP
Aesthetics ||| S:373 E:383 ||| NNP
,  ||| S:383 E:385 ||| ,
Scottsdale ||| S:385 E:395 ||| NNP
,  ||| S:395 E:397 ||| ,
AZ ||| S:397 E:399 ||| NNP
)  ||| S:399 E:401 ||| -RRB-
has  ||| S:401 E:405 ||| VBZ
been  ||| S:405 E:410 ||| VBN
made  ||| S:410 E:415 ||| VBN
available  ||| S:415 E:425 ||| JJ
in  ||| S:425 E:428 ||| IN
the  ||| S:428 E:432 ||| DT
United  ||| S:432 E:439 ||| NNP
States  ||| S:439 E:446 ||| NNPS
and  ||| S:446 E:450 ||| CC
these  ||| S:450 E:456 ||| DT
same  ||| S:456 E:461 ||| JJ
physiologic  ||| S:461 E:473 ||| JJ
effects  ||| S:473 E:481 ||| NNS
have  ||| S:481 E:486 ||| VBP
become  ||| S:486 E:493 ||| VBN
beneficial  ||| S:493 E:504 ||| JJ
clinical  ||| S:504 E:513 ||| JJ
targets ||| S:513 E:520 ||| NNS
.  ||| S:520 E:522 ||| .
This  ||| S:522 E:527 ||| DT
formulation  ||| S:527 E:539 ||| NN
has  ||| S:539 E:543 ||| VBZ
been  ||| S:543 E:548 ||| VBN
used  ||| S:548 E:553 ||| VBN
successfully  ||| S:553 E:566 ||| RB
for  ||| S:566 E:570 ||| IN
nearly  ||| S:570 E:577 ||| RB
20  ||| S:577 E:580 ||| CD
years  ||| S:580 E:586 ||| NNS
in  ||| S:586 E:589 ||| IN
Europe  ||| S:589 E:596 ||| NNP
and  ||| S:596 E:600 ||| CC
other  ||| S:600 E:606 ||| JJ
countries  ||| S:606 E:616 ||| NNS
under  ||| S:616 E:622 ||| IN
the  ||| S:622 E:626 ||| DT
trade  ||| S:626 E:632 ||| NN
name  ||| S:632 E:637 ||| NN
Dysport  ||| S:637 E:645 ||| NNP
( ||| S:645 E:646 ||| -LRB-
Clostridium  ||| S:646 E:658 ||| NNP
botulinum  ||| S:658 E:668 ||| JJ
type  ||| S:668 E:673 ||| NN
A  ||| S:673 E:675 ||| DT
toxin-hemagglutinin  ||| S:675 E:695 ||| JJ
complex ||| S:695 E:702 ||| NN
;  ||| S:702 E:704 ||| :
Ipsen  ||| S:704 E:710 ||| NNP
Biopharm ||| S:710 E:718 ||| NNP
,  ||| S:718 E:720 ||| ,
Wrexham ||| S:720 E:727 ||| NNP
,  ||| S:727 E:729 ||| ,
UK ||| S:729 E:731 ||| NNP
) ||| S:731 E:732 ||| -RRB-
.  ||| S:732 E:734 ||| .
BoNT-A  ||| S:734 E:741 ||| JJ
injections  ||| S:741 E:752 ||| NNS
are  ||| S:752 E:756 ||| VBP
administered  ||| S:756 E:769 ||| VBN
to  ||| S:769 E:772 ||| TO
achieve  ||| S:772 E:780 ||| VB
temporary  ||| S:780 E:790 ||| JJ
local  ||| S:790 E:796 ||| JJ
flaccid  ||| S:796 E:804 ||| JJ
paralysis  ||| S:804 E:814 ||| NN
of  ||| S:814 E:817 ||| IN
targeted  ||| S:817 E:826 ||| JJ
muscles ||| S:826 E:833 ||| NNS
.  ||| S:833 E:835 ||| .
Injection  ||| S:835 E:845 ||| NN
of  ||| S:845 E:848 ||| IN
BoNT-A  ||| S:848 E:855 ||| JJ
formulations  ||| S:855 E:868 ||| NNS
for  ||| S:868 E:872 ||| IN
aesthetic  ||| S:872 E:882 ||| JJ
purposes  ||| S:882 E:891 ||| NNS
was  ||| S:891 E:895 ||| VBD
by  ||| S:895 E:898 ||| IN
far  ||| S:898 E:902 ||| RB
the  ||| S:902 E:906 ||| DT
most  ||| S:906 E:911 ||| RBS
common  ||| S:911 E:918 ||| JJ
minimally-invasive  ||| S:918 E:937 ||| NN
( ||| S:937 E:938 ||| -LRB-
nonsurgical ||| S:938 E:949 ||| LS
)  ||| S:949 E:951 ||| -RRB-
cosmetic  ||| S:951 E:960 ||| JJ
procedure  ||| S:960 E:970 ||| NN
performed  ||| S:970 E:980 ||| VBN
in  ||| S:980 E:983 ||| IN
the  ||| S:983 E:987 ||| DT
United  ||| S:987 E:994 ||| NNP
States  ||| S:994 E:1001 ||| NNPS
in  ||| S:1001 E:1004 ||| IN
2008 ||| S:1004 E:1008 ||| CD
.  ||| S:1008 E:1010 ||| .
The  ||| S:1010 E:1014 ||| DT
objective  ||| S:1014 E:1024 ||| NN
of  ||| S:1024 E:1027 ||| IN
this  ||| S:1027 E:1032 ||| DT
review  ||| S:1032 E:1039 ||| NN
is  ||| S:1039 E:1042 ||| VBZ
to  ||| S:1042 E:1045 ||| TO
describe  ||| S:1045 E:1054 ||| VB
the  ||| S:1054 E:1058 ||| DT
latest  ||| S:1058 E:1065 ||| JJS
data  ||| S:1065 E:1070 ||| NNS
regarding  ||| S:1070 E:1080 ||| VBG
the  ||| S:1080 E:1084 ||| DT
mechanism  ||| S:1084 E:1094 ||| NN
of  ||| S:1094 E:1097 ||| IN
action  ||| S:1097 E:1104 ||| NN
of  ||| S:1104 E:1107 ||| IN
BoNTA-ABO ||| S:1107 E:1116 ||| NNP
,  ||| S:1116 E:1118 ||| ,
the  ||| S:1118 E:1122 ||| DT
potential  ||| S:1122 E:1132 ||| JJ
roles  ||| S:1132 E:1138 ||| NNS
of  ||| S:1138 E:1141 ||| IN
neurotoxin-associated  ||| S:1141 E:1163 ||| JJ
proteins  ||| S:1163 E:1172 ||| NNS
( ||| S:1172 E:1173 ||| -LRB-
NAP ||| S:1173 E:1176 ||| NNP
) ||| S:1176 E:1177 ||| -RRB-
,  ||| S:1177 E:1179 ||| ,
the  ||| S:1179 E:1183 ||| DT
manufacturing  ||| S:1183 E:1197 ||| NN
standards  ||| S:1197 E:1207 ||| NNS
for  ||| S:1207 E:1211 ||| IN
these  ||| S:1211 E:1217 ||| DT
biologic  ||| S:1217 E:1226 ||| JJ
products ||| S:1226 E:1234 ||| NNS
,  ||| S:1234 E:1236 ||| ,
and  ||| S:1236 E:1240 ||| CC
the  ||| S:1240 E:1244 ||| DT
specific  ||| S:1244 E:1253 ||| JJ
manufacturing  ||| S:1253 E:1267 ||| NN
process  ||| S:1267 E:1275 ||| NN
and  ||| S:1275 E:1279 ||| CC
characteristics  ||| S:1279 E:1295 ||| NNS
of  ||| S:1295 E:1298 ||| IN
BoNTA-ABO ||| S:1298 E:1307 ||| JJ
.  ||| S:1307 E:1309 ||| .
A  ||| S:1309 E:1311 ||| DT
systematic  ||| S:1311 E:1322 ||| JJ
search  ||| S:1322 E:1329 ||| NN
using  ||| S:1329 E:1335 ||| VBG
the  ||| S:1335 E:1339 ||| DT
US  ||| S:1339 E:1342 ||| NNP
National  ||| S:1342 E:1351 ||| NNP
Library  ||| S:1351 E:1359 ||| NNP
of  ||| S:1359 E:1362 ||| IN
Medicine  ||| S:1362 E:1371 ||| NNP
PubMed  ||| S:1371 E:1378 ||| JJ
database  ||| S:1378 E:1387 ||| NN
was  ||| S:1387 E:1391 ||| VBD
performed  ||| S:1391 E:1401 ||| VBN
and  ||| S:1401 E:1405 ||| CC
the  ||| S:1405 E:1409 ||| DT
relevant  ||| S:1409 E:1418 ||| JJ
articles  ||| S:1418 E:1427 ||| NNS
were  ||| S:1427 E:1432 ||| VBD
reviewed ||| S:1432 E:1440 ||| VBN
.  ||| S:1440 E:1442 ||| .
Direct  ||| S:1442 E:1449 ||| JJ
input  ||| S:1449 E:1455 ||| NN
and  ||| S:1455 E:1459 ||| CC
data  ||| S:1459 E:1464 ||| NNS
from  ||| S:1464 E:1469 ||| IN
the  ||| S:1469 E:1473 ||| DT
worldwide  ||| S:1473 E:1483 ||| JJ
manufacturer  ||| S:1483 E:1496 ||| NN
of  ||| S:1496 E:1499 ||| IN
Dysport  ||| S:1499 E:1507 ||| NNP
have  ||| S:1507 E:1512 ||| VBP
been  ||| S:1512 E:1517 ||| VBN
included ||| S:1517 E:1525 ||| VBN
.  ||| S:1525 E:1527 ||| .
The  ||| S:1527 E:1531 ||| DT
four  ||| S:1531 E:1536 ||| CD
sequential  ||| S:1536 E:1547 ||| CD
steps  ||| S:1547 E:1553 ||| NNS
in  ||| S:1553 E:1556 ||| IN
the  ||| S:1556 E:1560 ||| DT
mechanism  ||| S:1560 E:1570 ||| NN
of  ||| S:1570 E:1573 ||| IN
action  ||| S:1573 E:1580 ||| NN
of  ||| S:1580 E:1583 ||| IN
BoNTA-ABO  ||| S:1583 E:1593 ||| NNS
are  ||| S:1593 E:1597 ||| VBP
binding ||| S:1597 E:1604 ||| JJ
,  ||| S:1604 E:1606 ||| ,
internalization ||| S:1606 E:1621 ||| NN
,  ||| S:1621 E:1623 ||| ,
translocation ||| S:1623 E:1636 ||| NN
,  ||| S:1636 E:1638 ||| ,
and  ||| S:1638 E:1642 ||| CC
intracellular  ||| S:1642 E:1656 ||| JJ
proteolysis  ||| S:1656 E:1668 ||| NN
of  ||| S:1668 E:1671 ||| IN
the  ||| S:1671 E:1675 ||| DT
target  ||| S:1675 E:1682 ||| NN
protein ||| S:1682 E:1689 ||| NN
.  ||| S:1689 E:1691 ||| .
Although  ||| S:1691 E:1700 ||| IN
all  ||| S:1700 E:1704 ||| DT
BoNT-A  ||| S:1704 E:1711 ||| JJ
products  ||| S:1711 E:1720 ||| NNS
must  ||| S:1720 E:1725 ||| MD
meet  ||| S:1725 E:1730 ||| VB
standards  ||| S:1730 E:1740 ||| NNS
for  ||| S:1740 E:1744 ||| IN
quality ||| S:1744 E:1751 ||| NN
,  ||| S:1751 E:1753 ||| ,
potency ||| S:1753 E:1760 ||| NN
,  ||| S:1760 E:1762 ||| ,
and  ||| S:1762 E:1766 ||| CC
safety ||| S:1766 E:1772 ||| NN
,  ||| S:1772 E:1774 ||| ,
they  ||| S:1774 E:1779 ||| PRP
should  ||| S:1779 E:1786 ||| MD
not  ||| S:1786 E:1790 ||| RB
be  ||| S:1790 E:1793 ||| VB
considered  ||| S:1793 E:1804 ||| VBN
equivalent  ||| S:1804 E:1815 ||| JJ
formulations  ||| S:1815 E:1828 ||| NNS
because  ||| S:1828 E:1836 ||| IN
they  ||| S:1836 E:1841 ||| PRP
have  ||| S:1841 E:1846 ||| VBP
different  ||| S:1846 E:1856 ||| JJ
production  ||| S:1856 E:1867 ||| NN
strains  ||| S:1867 E:1875 ||| NNS
of  ||| S:1875 E:1878 ||| IN
the  ||| S:1878 E:1882 ||| DT
bacterium  ||| S:1882 E:1892 ||| NN
C  ||| S:1892 E:1894 ||| NNP
botulinum ||| S:1894 E:1903 ||| NN
,  ||| S:1903 E:1905 ||| ,
as  ||| S:1905 E:1908 ||| RB
well  ||| S:1908 E:1913 ||| RB
as  ||| S:1913 E:1916 ||| IN
different  ||| S:1916 E:1926 ||| JJ
isolation  ||| S:1926 E:1936 ||| NN
and  ||| S:1936 E:1940 ||| CC
manufacturing  ||| S:1940 E:1954 ||| NN
processes  ||| S:1954 E:1964 ||| VBZ
that  ||| S:1964 E:1969 ||| DT
result  ||| S:1969 E:1976 ||| NN
in  ||| S:1976 E:1979 ||| IN
unique  ||| S:1979 E:1986 ||| JJ
product  ||| S:1986 E:1994 ||| NN
characteristics ||| S:1994 E:2009 ||| NNS
.  ||| S:2009 E:2011 ||| .
The  ||| S:2011 E:2015 ||| DT
production  ||| S:2015 E:2026 ||| NN
steps  ||| S:2026 E:2032 ||| NNS
for  ||| S:2032 E:2036 ||| IN
Dysport-including  ||| S:2036 E:2054 ||| JJ
a  ||| S:2054 E:2056 ||| DT
unique  ||| S:2056 E:2063 ||| JJ
proprietary  ||| S:2063 E:2075 ||| JJ
purification  ||| S:2075 E:2088 ||| JJ
process  ||| S:2088 E:2096 ||| NN
using  ||| S:2096 E:2102 ||| VBG
column  ||| S:2102 E:2109 ||| NN
chromatography  ||| S:2109 E:2124 ||| NNS
and  ||| S:2124 E:2128 ||| CC
a  ||| S:2128 E:2130 ||| DT
unique  ||| S:2130 E:2137 ||| JJ
proprietary  ||| S:2137 E:2149 ||| NN
finishing  ||| S:2149 E:2159 ||| VBG
process-result  ||| S:2159 E:2174 ||| JJ
in  ||| S:2174 E:2177 ||| IN
consistent  ||| S:2177 E:2188 ||| JJ
and  ||| S:2188 E:2192 ||| CC
unique  ||| S:2192 E:2199 ||| JJ
product  ||| S:2199 E:2207 ||| NN
features ||| S:2207 E:2215 ||| NNS
.  ||| S:2215 E:2217 ||| .
Studies  ||| S:2217 E:2225 ||| NNS
confirm  ||| S:2225 E:2233 ||| VBP
that  ||| S:2233 E:2238 ||| IN
Dysport  ||| S:2238 E:2246 ||| NNP
has  ||| S:2246 E:2250 ||| VBZ
a  ||| S:2250 E:2252 ||| DT
high  ||| S:2252 E:2257 ||| JJ
degree  ||| S:2257 E:2264 ||| NN
of  ||| S:2264 E:2267 ||| IN
long-term  ||| S:2267 E:2277 ||| JJ
batch-to-batch  ||| S:2277 E:2292 ||| JJ
consistency  ||| S:2292 E:2304 ||| NN
for  ||| S:2304 E:2308 ||| IN
a  ||| S:2308 E:2310 ||| DT
range  ||| S:2310 E:2316 ||| NN
of  ||| S:2316 E:2319 ||| IN
specified  ||| S:2319 E:2329 ||| JJ
properties ||| S:2329 E:2339 ||| NNS
,  ||| S:2339 E:2341 ||| ,
including  ||| S:2341 E:2351 ||| VBG
specific  ||| S:2351 E:2360 ||| JJ
potency ||| S:2360 E:2367 ||| NN
,  ||| S:2367 E:2369 ||| ,
protein  ||| S:2369 E:2377 ||| NN
composition ||| S:2377 E:2388 ||| NN
,  ||| S:2388 E:2390 ||| ,
toxin  ||| S:2390 E:2396 ||| NN
complex  ||| S:2396 E:2404 ||| JJ
charge-density  ||| S:2404 E:2419 ||| JJ
properties ||| S:2419 E:2429 ||| NNS
,  ||| S:2429 E:2431 ||| ,
and  ||| S:2431 E:2435 ||| CC
endopeptidase  ||| S:2435 E:2449 ||| JJ
activity ||| S:2449 E:2457 ||| NN
.  ||| S:2457 E:2459 ||| .
In  ||| S:2459 E:2462 ||| IN
the  ||| S:2462 E:2466 ||| DT
native ||| S:2466 E:2472 ||| NN
,  ||| S:2472 E:2474 ||| ,
natural  ||| S:2474 E:2482 ||| JJ
form ||| S:2482 E:2486 ||| NN
,  ||| S:2486 E:2488 ||| ,
NAP  ||| S:2488 E:2492 ||| NNP
protect  ||| S:2492 E:2500 ||| VB
the  ||| S:2500 E:2504 ||| DT
endogenous  ||| S:2504 E:2515 ||| JJ
neurotoxin  ||| S:2515 E:2526 ||| NN
from  ||| S:2526 E:2531 ||| IN
degradation  ||| S:2531 E:2543 ||| NN
in  ||| S:2543 E:2546 ||| IN
the  ||| S:2546 E:2550 ||| DT
acidic  ||| S:2550 E:2557 ||| JJ
environment  ||| S:2557 E:2569 ||| NN
of  ||| S:2569 E:2572 ||| IN
the  ||| S:2572 E:2576 ||| DT
stomach ||| S:2576 E:2583 ||| NN
;  ||| S:2583 E:2585 ||| :
in  ||| S:2585 E:2588 ||| IN
biologic  ||| S:2588 E:2597 ||| JJ
formulations ||| S:2597 E:2609 ||| NNS
,  ||| S:2609 E:2611 ||| ,
they  ||| S:2611 E:2616 ||| PRP
may  ||| S:2616 E:2620 ||| MD
have  ||| S:2620 E:2625 ||| VB
effects  ||| S:2625 E:2633 ||| NNS
on  ||| S:2633 E:2636 ||| IN
the  ||| S:2636 E:2640 ||| DT
structural  ||| S:2640 E:2651 ||| JJ
stability ||| S:2651 E:2660 ||| NN
,  ||| S:2660 E:2662 ||| ,
binding ||| S:2662 E:2669 ||| JJ
,  ||| S:2669 E:2671 ||| ,
uptake ||| S:2671 E:2677 ||| NN
,  ||| S:2677 E:2679 ||| ,
and  ||| S:2679 E:2683 ||| CC
transcytosis  ||| S:2683 E:2696 ||| NN
of  ||| S:2696 E:2699 ||| IN
BoNT-A  ||| S:2699 E:2706 ||| JJ
products  ||| S:2706 E:2715 ||| NNS
in  ||| S:2715 E:2718 ||| IN
other  ||| S:2718 E:2724 ||| JJ
areas  ||| S:2724 E:2730 ||| NNS
of  ||| S:2730 E:2733 ||| IN
the  ||| S:2733 E:2737 ||| DT
body ||| S:2737 E:2741 ||| NN
.  ||| S:2741 E:2743 ||| .
NAP  ||| S:2743 E:2747 ||| NNP
are  ||| S:2747 E:2751 ||| VBP
most  ||| S:2751 E:2756 ||| RBS
likely  ||| S:2756 E:2763 ||| JJ
to  ||| S:2763 E:2766 ||| TO
stabilize  ||| S:2766 E:2776 ||| VB
the  ||| S:2776 E:2780 ||| DT
neurotoxin  ||| S:2780 E:2791 ||| NN
in  ||| S:2791 E:2794 ||| IN
a  ||| S:2794 E:2796 ||| DT
vial  ||| S:2796 E:2801 ||| NN
of  ||| S:2801 E:2804 ||| IN
clinical  ||| S:2804 E:2813 ||| JJ
product ||| S:2813 E:2820 ||| NN
.  ||| S:2820 E:2822 ||| .
A  ||| S:2822 E:2824 ||| DT
thorough  ||| S:2824 E:2833 ||| JJ
understanding  ||| S:2833 E:2847 ||| NN
of  ||| S:2847 E:2850 ||| IN
the  ||| S:2850 E:2854 ||| DT
mechanism  ||| S:2854 E:2864 ||| NN
of  ||| S:2864 E:2867 ||| IN
action ||| S:2867 E:2873 ||| NN
,  ||| S:2873 E:2875 ||| ,
product  ||| S:2875 E:2883 ||| NN
characteristics ||| S:2883 E:2898 ||| NNS
,  ||| S:2898 E:2900 ||| ,
and  ||| S:2900 E:2904 ||| CC
effects  ||| S:2904 E:2912 ||| NNS
of  ||| S:2912 E:2915 ||| IN
NAP  ||| S:2915 E:2919 ||| NNP
is  ||| S:2919 E:2922 ||| VBZ
important  ||| S:2922 E:2932 ||| JJ
to  ||| S:2932 E:2935 ||| TO
ensure  ||| S:2935 E:2942 ||| VB
appropriate  ||| S:2942 E:2954 ||| JJ
and  ||| S:2954 E:2958 ||| CC
safe  ||| S:2958 E:2963 ||| JJ
clinical  ||| S:2963 E:2972 ||| JJ
use  ||| S:2972 E:2976 ||| NN
of  ||| S:2976 E:2979 ||| IN
BoNT-A  ||| S:2979 E:2986 ||| JJ
products ||| S:2986 E:2994 ||| NNS
.  ||| S:2994 E:2996 ||| .
Now  ||| S:2996 E:3000 ||| RB
approved  ||| S:3000 E:3009 ||| VBN
in  ||| S:3009 E:3012 ||| IN
the  ||| S:3012 E:3016 ||| DT
United  ||| S:3016 E:3023 ||| NNP
States ||| S:3023 E:3029 ||| NNPS
,  ||| S:3029 E:3031 ||| ,
Dysport  ||| S:3031 E:3039 ||| NNP
is  ||| S:3039 E:3042 ||| VBZ
an  ||| S:3042 E:3045 ||| DT
important  ||| S:3045 E:3055 ||| JJ
addition  ||| S:3055 E:3064 ||| NN
to  ||| S:3064 E:3067 ||| TO
the  ||| S:3067 E:3071 ||| DT
group  ||| S:3071 E:3077 ||| NN
of  ||| S:3077 E:3080 ||| IN
available  ||| S:3080 E:3090 ||| JJ
BoNT-A  ||| S:3090 E:3097 ||| JJ
formulations ||| S:3097 E:3109 ||| NNS
.  ||| S:3109 E:3111 ||| .
